Israel · Delayed Price · Currency is ILS · Price in ILA Nextgen Biomed Statistics
Total Valuation
Nextgen Biomed has a market cap or net worth of ILS 7.21 million. The enterprise value is 7.27 million.
| Market Cap | 7.21M |
| Enterprise Value | 7.27M |
Important Dates
The next estimated earnings date is Thursday, November 27, 2025.
| Earnings Date | Nov 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Nextgen Biomed has 14.80 million shares outstanding. The number of shares has increased by 15.90% in one year.
| Current Share Class | 14.80M |
| Shares Outstanding | 14.80M |
| Shares Change (YoY) | +15.90% |
| Shares Change (QoQ) | +20.30% |
| Owned by Insiders (%) | 17.44% |
| Owned by Institutions (%) | 7.03% |
| Float | 12.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -2.92 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.49 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.36 |
Financial Position
The company has a current ratio of 0.08
| Current Ratio | 0.08 |
| Quick Ratio | 0.05 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.10 |
| Interest Coverage | -203.13 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -728.92% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 207.54% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.63M |
| Employee Count | 3 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.01% in the last 52 weeks. The beta is 0.92, so Nextgen Biomed's price volatility has been similar to the market average.
| Beta (5Y) | 0.92 |
| 52-Week Price Change | -29.01% |
| 50-Day Moving Average | 41.29 |
| 200-Day Moving Average | 55.84 |
| Relative Strength Index (RSI) | 16.69 |
| Average Volume (20 Days) | 36,451 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -4.88M |
| Pretax Income | -4.90M |
| Net Income | -4.89M |
| EBITDA | -4.78M |
| EBIT | -4.88M |
| Earnings Per Share (EPS) | -0.58 |
Balance Sheet
The company has 35,000 in cash and 222,000 in debt, giving a net cash position of -187,000 or -0.01 per share.
| Cash & Cash Equivalents | 35,000 |
| Total Debt | 222,000 |
| Net Cash | -187,000 |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | -2.47M |
| Book Value Per Share | -0.21 |
| Working Capital | -2.70M |
Cash Flow
In the last 12 months, operating cash flow was -2.06 million and capital expenditures -102,000, giving a free cash flow of -2.16 million.
| Operating Cash Flow | -2.06M |
| Capital Expenditures | -102,000 |
| Free Cash Flow | -2.16M |
| FCF Per Share | -0.15 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Nextgen Biomed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.90% |
| Shareholder Yield | -15.90% |
| Earnings Yield | -67.88% |
| FCF Yield | -30.03% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 3, 2023. It was a reverse split with a ratio of 0.1666666667.
| Last Split Date | Sep 3, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.1666666667 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |